

The FLAMIN-GO project

Annalisa CHIOCCETTI, University of Piemonte Orientale

FLAMIN-GO aims at developing an Organ-on-Chip (OoC) technology for innovative clinical trials on Rheumatoid Arthritis (RA). In RA, a number of unmet needs still persist particularly related to response/non-response of powerful but expensive drugs. Conventional clinical trials may address part of these challenges, but are time consuming, expensive and ethically doubtful as part of the patients still fail to achieve disease benefits. Thus, the rheumatology community has a need for an alternative strategy that can deliver innovative trials. FLAMIN-GO will develop a personalized next-generation joint-on-chip that, by effectively mimicking the complexity of RA joint, will allow performing personalized clinical trials-on-chip. When validated, the platform will also be a turning point for i) pharma, by enabling screening of new drugs and for ii) translational research, for identification of new biomarkers or therapeutic targets.